SymITA: Switch to DRV/COB/FTC/TAF From Integrase Containing Regimens to Evaluate Changes in Tolerability/Adherence
Latest Information Update: 25 Sep 2024
At a glance
- Drugs Cobicistat/darunavir/emtricitabine/tenofovir alafenamide (Primary)
- Indications HIV-1 infections
- Focus Adverse reactions; Therapeutic Use
- Acronyms SymITA
Most Recent Events
- 03 Dec 2021 Status changed from not yet recruiting to withdrawn prior to enrolment. Reason the study was stopped was provided as lack of eligible enrollees/ halted by primary sponsor.
- 04 Feb 2020 New trial record